Viva Biotech (01873.HK): Rapid CRO business growth accelerates construction of CRO-CDMO integrated platform
VIA Biotech (1873.HK) 2021 Annual Report Review: CRO Business Is Growing Rapidly, CDMO Business Is Still Waiting to Bloom
Zheshang Securities: optimistic that the CXO rebound window is coming
ViaBio (1873.HK): Results continued to grow rapidly in the first half of the year and multi-business synergies will gradually become apparent
Viva Biotech (1873.HK): Drug discovery business maintained rapid growth, and CDMO business showed negative growth due to limited production capacity
VIA Biotech (1873.HK): Normalization of equity incentive mechanisms, medium- to long-term strategic optimism for corporate drug discovery, and CDMO's integrated service platform
Viva Biotech (1873.HK): Leading global structure-based drug discovery market leader merges Langhua Pharmaceuticals strategically enters the CDMO circuit
VIA Biotech (1873.HK) In-depth Report: Building an Integrated New Drug Development Ecosystem Based on Structural Drug Discovery and CRO Lead Service+Incubation
Viva Biotech (01873.HK): Langhua's merger brings growth, new engines, drug discovery, CRO and investment incubation businesses continue to empower global innovation
ViaBio (01873.HK): Revenue continues to grow rapidly throughout the year, and the industrial chain layout is getting better
ViviaBio (1873.HK): Endogenous High Growth Integration Begins
ViviaBio (1873.HK): Langhua's merger and acquisition integration progressed smoothly, CFS and EFS businesses went hand in hand
VIA Biotech (01873.HK) Important Event Review: Expanding the Service Chain and Small Molecule CDMO Acquisitions Reach a New Ceiling
维亚生物(01873):医药CXO+投资协同推进的一体化平台
VIA Biotech (01873.HK) In-depth Report: An Integrated Platform for Collaborative Promotion of Pharmaceutical CXO+ Investment
Guoxin Securities: It is expected that there will be a lot of room for improvement in drug discovery demand in the future. It is recommended to buy shares such as Pharmaceutical Mingkang (02359) and Kanglong Chemical (03759)
维亚生物(01873.HK):业务向下游延伸顺利 EFS模式逐步验证
Zheshang Securities: CXO sector pullback, focusing on drug screening CRO in business model verification
ViaBio (01873.HK): High order growth, EFS business progressing smoothly
维亚生物(1873.HK):20H1订单超预期 掌握流量的小CRO有大空间
No Data